Monopar Therapeutics (MNPR) has filed a preliminary prospectus for a $40M IPO.
The Wilmette, IL-based clinical-stage biopharmaceutical firm develops cancer treatments that it either in-licenses or outright acquires. Lead candidate is Phase 3-stage, Fast Track-tagged Validive (clonidine mucobuccal tablet) for the potential treatment of oral mucositis in patients undergoing chemoradiotherapy for oropharyngeal cancer. The company in-licensed the rights from Onxeo S.A. about two years ago.
2019 Financials (6 mo.): Operating Expenses: $2.3M; Net Loss: ($2.3M); Cash Burn: ($174K).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.